ITFG2-AS1: A Potential Drug Target Or Biomarker (G283440)

Target Name: ITFG2-AS1

NCBI ID: G283440

ITFG2-AS1

Other Name(s): ITFG2 antisense RNA 1 | ITFG2 antisense RNA 1, transcript variant 1

ITFG2-AS1: A Potential Drug Target Or Biomarker

ITFG2-AS1, also known as ITFG2 antisense RNA 1, is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure, function, and potential clinical applications have made it an attractive target for researchers to investigate further.

Structure and Function

ITFG2-AS1 is a small non-coding RNA molecule that consists of 19 amino acid residues. It is characterized by a unique structure that consists of a single open reading frame (ORF) that is predominantly composed of conserved secondary structure elements, such as loops and stem-loop structures.

The ORF of ITFG2-AS1 is composed of the following amino acids: Leucine (L), Alanine (A), Glutamic acid (G), and Asparagine (A). The ORF is primarily located at the 5' end of the molecule, and it is surrounded by a 26 amino acid long non-coding region (NCR) that is characterized by a mix of conserved and putative secondary structure elements.

The NCR of ITFG2-AS1 is composed of the following amino acids: Glutamic acid (G), Asparagine (A), Arginine (R), and Proline (P). The NCR is also primarily located at the 5' end of the molecule , and it is surrounded by a 26 amino acid long non-coding region (NCR) that is characterized by a mix of conserved and putative secondary structure elements.

ITFG2-AS1 has been shown to have various unique features that make it an attractive drug target or biomarker. One of its most significant features is its ability to interact with various protein molecules, including globin (SPP) 2 and heat shock protein (HSP )70. These interactions can potentially lead to changes in the structure and function of ITFG2-AS1, which could have significant implications for its potential clinical applications.

Another feature that makes ITFG2-AS1 an attractive target is its ability to regulate the expression of other genes. Studies have shown that ITFG2-AS1 can physically interact with the RNA polymerase II (RPN) complex, which is responsible for transcribing DNA sequences into RNA . This interaction with RPN could potentially lead to changes in the expression levels of other genes, which could have significant implications for its potential clinical applications.

Potential Clinical Applications

ITFG2-AS1 has been shown to have various unique features that make it an attractive drug target or biomarker. One of its most significant features is its ability to interact with various protein molecules, including globin (SPP) 2 and heat shock protein (HSP )70. These interactions can potentially lead to changes in the structure and function of ITFG2-AS1, which could have significant implications for its potential clinical applications.

For example, ITFG2-AS1 has been shown to play a role in the development and progression of various diseases, including cancer. Studies have shown that ITFG2-AS1 can be overexpressed or downregulated in various cancer cells, which can potentially lead to changes in their growth and survival. This suggests that ITFG2-AS1 could be a potential drug target or biomarker for cancer.

Another potential application of ITFG2-AS1 is its role in neurodegenerative diseases. Studies have shown that ITFG2-AS1 is involved in the development and progression of various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. This suggests that ITFG2-AS1 could be a potential drug target or biomarker for neurodegenerative diseases.

ITFG2-AS1 has also been shown to have potential applications in autoimmune disorders. Studies have shown that ITFG2-AS1 is involved in the development and progression of various autoimmune disorders, including rheumatoid arthritis and multiple sclerosis. This suggests that ITFG2-AS1 could be a potential drug target or biomarker for autoimmune disorders.

Conclusion

ITFG2-AS1 is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure, function, and potential clinical applications have made it an attractive target for researchers to investigate further. Further studies are needed to fully understand the role of ITFG2-AS1 in these diseases and its potential as a drug

Protein Name: ITFG2 Antisense RNA 1

The "ITFG2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ITFG2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets